Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Merck wins 1st FDA approval for Keytruda
Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated with asbestos.
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
USFDA nod to Merck KEYTRUDA plus Pemetrexed, Platinum Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S.Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination
Merck’s Keytruda approved by FDA as first-line malignant pleural mesothelioma treatment
Merck & Co – known as MSD outside the US and Canada – has received approval from the US Food and Drug Administration (FDA) for the use of Keytruda (pembrolizumab) in malignant pleural mesothelioma. The anti-PD-1 therapy has been approved in combination with pemetrexed and platinum chemotherapy as a first-line treatment for adults with unresectable advanced or metastatic cases of the disease.
Merck’s Keytruda label expanded in the U.S. for mesothelioma
Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its blockbuster therapy Keytruda to allow its use as a first-line combination therapy for mesothelioma,
10d
on MSN
Merck Keytruda cuts mortality risk by 33% in late-stage trial for cervical cancer
Keytruda shows promise as a first line option in cervical cancer cutting patients' mortality risk by a third in a Phase 3 ...
Daily
16h
Merck gets positive EU CHMP opinions for Keytruda regimens for patients with two types of Gynecologic cancers
Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's ...
FiercePharma
9d
ESMO: With survival win, Merck's Keytruda redeems itself in early triple-negative breast cancer
In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...
BioSpace
6d
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has Something to Prove
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
10d
Where Will Merck Stock Be in 5 Years?
Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...
FiercePharma
10d
ESMO: Merck unpacks a mixed bag of gynecological cancer results for Keytruda
Even for Merck’s oncology powerhouse Keytruda, the emerging role of immunotherapies in gynecological cancer treatment ...
9d
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Pembrolizumab
Food and Drug Administration
Feedback